ClinicalTrials.gg
Status unknownNCT06410053AIIDUpdated May 10, 2024

The All Ireland Infectious Diseases Cohort Project

An observational study in Infectious Disease, sponsored by University College Dublin. Status unknown at 9 sites in Ireland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by University College Dublin · Observational

The sponsor has not verified this record recently (last verified May 2024), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The All-Ireland Infectious Diseases (AIID) Cohort is a multicentre, prospective, longitudinal observational cohort that enrols consecutive adult subjects attending participating institutions for infectious disease services. This is an ongoing prospective observational cohort of unlimited duration.

Read the detailed description

The All-Ireland Infectious Diseases cohort study (AIID Cohort) is enrolling patients at a number of Irish Hospitals with infectious diseases, including Covid-19. The AIID Cohort is a multicentre, prospective, longitudinal, observational cohort that enrols consecutive adult subjects (>18 years old) attending hospitals services for management of infections.

Subjects provide consent for use of routine clinical and laboratory data for research. All data is collected by a combination of retrospective medical note review and extraction of data from electronic health records. At a minimum, the following data items are to be collected at enrolment and subsequent clinic visits:

  1. Demography and basic information (e.g. date of birth, gender, country of origin, ethnicity, anthropometric assessments, and reasons for the attendance, date or year for disease diagnosis and transmission risk.
  2. Laboratory data: Relevant routine virological (including genotyping) and immunological data for characterisation of the HIV infection, TB, hepatitis C, COVID-19 and other relevant co-infections will also be collected as well as other relevant clinical routine data on tolerability and safety (i.e., renal, liver, lipids)
  3. Medical treatment: All medications, including start-and stop dates and reason for discontinuation, adherence. Concomitant medical treatment related to co-infections and co-morbidities.
  4. Clinical events: hospitalisation, diseases specific relevant active and previous diagnosis (e.g., AIDS and non-AIDS events, including comorbidities).

In addition, subjects are asked to provide biological samples for up to five occasions every six months for bio-banking for host profiling and pathogen bio-repository. To provide flexibility for participants around requirements for fasting or scheduling, participants may be asked to attend to provide samples for biobanking outside of routine scheduled clinic visits. These stored samples provide the opportunity for future research studies investigating host factors associated with the response to infection.

The AIID Cohort is approved by local institutional review boards and all participants provide written, informed consent. Data and samples within the AIID Cohort are accessed through standardised Data Access Guidelines and all approved Data Access Requests are approved by the local Ethics Committee.

02

Conditions studied

  • Infectious Disease

Keywords

  • Human Immunodeficiency virus
  • COVID-19
  • Viral hepatitis
  • Skin and soft tissue infections
  • Bone infection
03

In context

Communicable Diseases

4,447 studies on the registry are indexed under Communicable Diseases; 514 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 240 across 1,501 observational studies indexed under Communicable Diseases.

Browse Communicable Diseases studies →

Lead sponsor

University College Dublin is the lead sponsor of 113 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients attending Clinical Services relating to infectious diseases at participating hospitals in Ireland who provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age patients attending clinical services of participating institutions with issues related to infectious diseases.
  • Willing and able to provide informed consent or
  • Provide deferred assent if an incapacitated or unconscious patient is unable to provide informed consent

Exclusion criteria

Exclusion criteria:

  • Patients under 18 years of age
  • Patients with learning disabilities, mental illness, or dementia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Establishment of data rich cohort

    Overall number of recruited participants and number of recruited participants with major conditions (COVID-19, HIV, TB)

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Cohort retention

    Number of subjects in care or mortality

    Time frame: through study completion, an average of 1 year

  2. Cohort associated metadata

    Number of subjects recruited to the cohort with completed metadata and biobanked samples

    Time frame: through study completion, an average of 1 year

07

Study locations

9 of 9 sites recruiting
  • Cork University Hospital
    Cork, Ireland
    • Corina Sadlier, Dr · Contact
    Recruiting
  • Our Lady of Lourdes Hospital, Drogheda
    Drogheda, Ireland
    • Justin Low, Dr · Contact
    Recruiting
  • St Vincent's University Hospital, Ireland
    Dublin, D4, Ireland
    • Eoin Feeney, Dr · Contact
    Recruiting
  • Mater Misericordiae University Hospital
    Dublin, Dublin 7, Ireland
    • Aoife Cotter, Dr · Contact
    • Alan Macken · Contact
    Recruiting
  • Beaumont Hospital
    Dublin, Ireland
    • Eoghan De Barra, Dr · Contact
    Recruiting
  • Children's Health Ireland at Crumlin
    Dublin, Ireland
    • Paddy Galvin, Dr · Contact
    Recruiting
  • St James's Hospital
    Dublin, Ireland
    • Fiona Lyons, Dr · Contact
    Recruiting
  • St Luke's General Hospital, Kilkenny
    Kilkenny, Ireland
    • Garry Courtney, Dr · Contact
    Recruiting
  • Wexford General Hospital
    Wexford, Ireland
    • Obada Yousef, Dr · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06410053
Collaborators
Beaumont Hospital, Children's Health Ireland, Cork University Hospital, Mater Misericordiae University Hospital, Our Lady of Lourdes Hospital, Drogheda, St. James's Hospital, Ireland, St. Luke's Hospital, Ireland, St Vincent's University Hospital, Ireland, Wexford General Hospital
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Mar 2011
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
May 10, 2024

Study contacts

Aoife Cotter, PhD
Contact
aoife.cotter@ucd.ie
Alan Macken
Contact
alan.macken@ucd.ie
Patrick Mallon, PhD, FRCPI
principal investigator · UCD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion